Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.36 |
| ▸ | PDE2A | O00408 | 3/20 | 0.33 |
| ▸ | CLK1 | P49759 | 1/20 | 0.31 |
| ▸ | CLK2 | P49760 | 1/20 | 0.31 |
| ▸ | HIPK1 | Q86Z02 | 1/20 | 0.31 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.31 |
| ▸ | HIPK3 | Q9H422 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22732833 | 0.90 | KDM4E (0.35) | RXRANR4A2PDE2A | |
| SCHEMBL24389533 | 0.88 | PDE2A (0.32) | RXRANR4A2PDE2ACLK1CLK2 | |
| SCHEMBL24389532 | 0.82 | KDM4E (0.34) | — | |
| SCHEMBL22732516 | 0.80 | USP1 (0.36) | PDE2ACLK1CLK2HIPK1HIPK2 | |
| SCHEMBL22745756 | 0.77 | RXRA (0.37) | RXRANR4A2CLK1CLK2HIPK1 | |
| SCHEMBL22712492 | 0.75 | KDM4E (0.42) | PDE2ALMNATSHR | |
| SCHEMBL26941926 | 0.74 | CLK1 (0.33) | CLK1CLK2HIPK1HIPK2HIPK3 | |
| SCHEMBL10073169 | 0.73 | RXRA (0.56) | RXRANR4A2LMNATSHR | |
| SCHEMBL22732811 | 0.71 | RAB9A (0.53) | RXRANR4A2LMNATSHR | |
| SCHEMBL22745802 | 0.70 | RXRA (0.47) | RXRANR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4289480-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | F. Hoffmann-La Roche AG (CH) | 2023-12-13 | — | — | EP | disclosed |
| US-20220135528-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | GENENTECH, INC. (US AND US TERRITORIES) | 2022-05-05 | — | — | US | disclosed |
| US-11208387-B2 | Macrocyclic broad spectrum antibiotics | GENENTECH, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200377463-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | GENENTECH, INC. | 2020-12-03 | — | — | US | disclosed |
| WO-2020243155-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | GENENTECH, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377463-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, CLPP, PEPD | RXRA 2669/4885NR4A2 3206/4885PDE2A 2960/4885 |
| US-20220135528-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, CLPP, PEPD | RXRA 2669/4885NR4A2 3206/4885PDE2A 2960/4885 |
| US-11208387-B2 | Macrocyclic broad spectrum antibiotics | MRPL21, CLPP, PEPD | RXRA 2669/4885NR4A2 3206/4885PDE2A 2960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.